In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 204 for your search:
Cancer Type/Condition:  Melanoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12PLK01, NCT01683188

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793

3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12PLK02, NCT01856023

4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-154, NCT01223248

6.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02649, ECOG-E1609, CDR0000692568, E1609, U10CA021115, NCT01274338

7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0875, NCI-2012-01349, NCT01644591

8.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO27826, 2011-004011-24, NCT01667419

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 115532, NCT01682083

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMEK162A2301, 2012-003593-51, NCT01763164

11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 11-002177, NCI-2013-00645, NCT01826864

12.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMEK162B2301, NCT01909453

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: ECP RIT, NCT00179790

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 200807728, NCT00925132

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110013, 11-C-0013, NCT01218867

16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441

17.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UPCC 01611, NCT01350401

18.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110170, 11-C-0170, NCT01369888

19.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2B3-101-CR-001, NCT01386580

20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2011-0073, NCT01409174

21.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: ADA1001, ATI001-101, NCT01397708

22.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7050-G000-901, NCT01433991

23.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 06611, NCT01497808

24.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Protocol 11952, NCT01512251

25.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMEK162X2110, 2011-005875-17, NCT01543698
1     
New Search